TetraLogic Pharmaceuticals Corporation TLOG, a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced that it has temporarily halted enrollment in the birinapant chronic hepatitis B multiple ascending dose trial, currently being conducted in Australia, due to cranial nerve palsies observed in the first cohort.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
